BioSpace News Archive

Non-profit Consortium is Actively Seeking New Projects for Investment and Resource Support

VK2809 Treatment Leads to Rapid Reduction in Steatosis, Inflammation and Liver Size in Mouse Model of Glycogen Storage Disease Type Ia (GSD Ia)

Teva Pharmaceutical Industries Ltd. today announced that new data on COPAXONE® (glatiramer acetate injection), a product for relapsing forms of multiple sclerosis (RMS), will be presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin, October 10-12, 2018.

Phase 1 study in patients with chronic rhinosinusitis demonstrated safety and tolerability after 24 weeks of continuous anti-inflammatory treatment with long-acting LYR-210

Families come together to share patient experience and treatment needs at an international conference in Rome, Italy

Verastem, Inc. today announced that the National Comprehensive Cancer Network® (NCCN®) added COPIKTRA™ (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for follicular lymphoma (FL).

Protagonist Therapeutics, Inc. today announced that Dr. William J. Sandborn will present clinical data from a Phase 2 study of PTG-100, the Company’s oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide that is being developed for treatment of ulcerative colitis, at the United European Gastroenterology Week meeting.

There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating form of MS characterized by gradual, irreversible worsening of disability, largely independent of relapses

More than 300 Property & Casualty and Collision Repair Executives Gather to Hear the Latest Technology Trends and Industry Insights from Mitchell Leaders

Bioiberica confirms, once again, their presence at CPhI Worldwide, the most important event for producers of pharmaceutical ingredients and solutions.